EpitogenX: embracing disruption through innovative technologies.
EpitogenX is a forward-thinking biotech with innovative platforms backed by a world-leading scientific team. We strive to improve global healthcare outcomes by offering innovative solutions and affordable products.
EpitogenX Ltd is a holding company aiming to build on the successes of its subsidiary, Vertebrate Antibodies Ltd, to transform the biotech industry by providing high-quality services and products for both the medical and veterinary sectors.
Our EpitoGen® and AI EpitoPrediktTM technologies come together to create a powerful game-changing platform that will transform diagnostics, vaccine design, biotherapeutics, and antibody development.
With the support of Innova Medical Group Inc, we also aim to provide accurate, simple, accessible, and affordable point-of-care testing systems.
Using AI models we offer in silico solutions, validated in vitro and applied to create prototype clinical products using EpitoGen® Technology.
Products developed using this technology are compatible with gold standard lab-based and point-of-care applications (i.e. ELISA, LFA, microfluidics), making them affordable and user friendly.
“To improve life by making accurate and affordable products accessible to community-based healthcare and middle/low-income countries”. At EpitogenX we are very proud of the important role we will play in providing our partners with the means to deliver clinical products.
“Our Vision is to make our game-changing EpitoGen® technology available globally to transform the diagnostic sector”
Strategic visionary and entrepreneur, Ayham Alnabulsi is a co-founder of EpitoGenX and its CTO. Previously, Ayham has also co-founded and led Vertebrate Antibodies and AiBiologics. Ayham has extensive knowledge in medical genetics, immunology and mathematics, and he is a co-inventor of the game-changer EpitoGen technology.
Dr. Abdo is a co-founder, director and CEO of EpitogenX Ltd. He previously co-founded AiBiologics and Vertebrate Antibodies, and served as COO and CSO respectively. Abdo has a unique combination of scientific, financial and commercial expertise with a successful track record in molecular medicine, biomarker discovery, bio-product development, bioinformatics and immunoassays optimisation.
Tiehui Wang is a co-founder of the company and brings dynamic technology innovation and insight from his 30 years+ experience in protein engineering. Tiehui has valuable expertise in medical technology innovation as the co-inventor of the game changing EpitoGen® platform. Previously, Tiehui cofounded AiBiologics and served as a Chief Scientist.
Yehfang Hu is an immunologist with a wealth of expertise on veterinary immunology, immunopathology and IVD product development.
Alex Wang joined the team in 2022 with expertise in the development and optimization of novel point-of-care testing platforms. Alex has a background in medical sciences with experience in biotechnology and medical applications.
Dr Falconer holds a BSc Honours in Microbiology, MSc in Medicine and therapeutics and PhD in Cognitive Neuroscience. He has been a researcher for nearly 2 decades having worked extensively in both the scientific and social sciences fields. His scientific and academic knowledge is backed up by various publications in scientific papers. He is also a playwright and has authored and produced many plays across the UK.
Craig brings a combination of scientific, logistic management and regulatory expertise to EpitoGenx, gained through working in professional environments.
Ralfs brings a unique combination of scientific,Research and Development, management and commercial experience to EpitoGenx. Ralfs is also an expert in pathophysiology with a strong background in clinical assay development.
Professor Murray is Emeritus Regius Professor of Anatomy. He was the lead consultant gastro-intestinal pathologist to NHS Grampian and for the Grampian Biorepository. Professor Murray is an internationally recognised pathologist with specific interests in gastro-intestinal pathology and antibody technologies.
Wei Pang (Associate Professor, Heriot-Watt University) is a computer scientist who is specialised in Bio-inspired Computing, Machine Learning, and Explainable AI. Wei will apply bio-inspired computing approaches to optimise existing AI tools and develop novel machine learning and data mining algorithms.
Professor Secombes (Emeritus Regius Chair of Natural History) is a renowned immunologist with a wealth of expertise on veterinary immunology and immunopathology.
Professor Secombes has made a lasting contribution to the characterisation and elucidation of immune systems in lower vertebrates, influencing in the process disease mitigation and vaccine development.
Ting-Yu brings a wealth of expertise in biology, biotechnology, proteome exploration and metabolomics analyses. Ting-Yu is an expert in investigating proteomics ans metabolics processes using the liquid-chromatography mass spectrometry (LC-MS/MS) platforms. This set of skills are ideal to quantify disease markers and establish accurate diagnostic products
Prof Mirela Delibegovic, FRSE, is a Professor in Diabetes Physiology with vast experience in metabolic diseases and cell signalling. She leads many translational projects including drug discovery using bioinformatic and medicinal chemistry approaches, in vitro and in vivo pre-clinical testing, patient derived organoid cultures and patient populations.
Dr Brittain-Long is a consultant physician with >25 years of clinical experience. He is a specialist in Infectious Diseases, General Medicine & Acute Medicine with an interest in diagnostics, from the molecular level to direct clinical care. His research & clinical expertise includes tick-borne infections, respiratory viruses, TB and NTM.
EpitogenX brings together two innovative platforms to create game-changing solutions.
EpitoPrediktTM is an AI software that can accurately identify immunodominant epitopes, a crucial component of diagnostic, prophylactic and immunotherapeutic vaccines.
The software is embedded with machine and deep learning algorithms which generate models that can provide accurate solutions for specific biological designs.
Our core technology is called EpitoGen®; a bioengineered recombinant scaffold that can display single or multiple epitopes/antigens, forming the basis of the diagnostic assay.
Both platforms create a self-learning system whereby data generated experimentally is used to train the AI models and improve their predictive accuracy.
Learn more about our current projects, the applications of our technology and the company news.
EpitogenX is delighted to announce the launch of an Innovate UK Knowledge Transfer Partnership (KTP) between our subsidiary, Vertebrate Antibodies, an
The diagnostic pathway in the UK follows a two-step approach using commonly available antibody screening tests. This process is lengthy, complex, expe
AN AI model to predict IgA epitopes Mucosal immunization has numerous advantages over needle-based administrations; improved safety, self-delivery, ca